Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group-Reference-Cited by-同舟云学术

Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group

Published:2024-01 Issue:1 Volume:11 Page:e62-e74
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Kröger Nicolaus,Bacigalupo Andrea,Barbui Tiziano,Ditschkowski Markus,Gagelmann Nico,Griesshammer Martin,Gupta Vikas,Hamad Nada,Harrison Claire,Hernandez-Boluda Juan Carlos,Koschmieder Steffen,Jain Tania,Mascarenhas John,Mesa Ruben,Popat Uday R,Passamonti Francesco,Polverelli Nicola,Rambaldi Alessandro,Robin Marie,Salit Rachel B,Schroeder Thomas,Scott Bart L,Tamari Roni,Tefferi Ayalew,Vannucchi Alessandro M,McLornan Donal P,Barosi Giovanni

Publisher

Elsevier BV

Subject

Hematology

Reference76 articles.

1. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group;Kröger;Leukemia,2015

2. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management;Tefferi;Am J Hematol,2023

3. Appraising a tool for guideline appraisal (the AGREE II instrument);Dans;J Clin Epidemiol,2010

4. The technology assessment and practice guidelines forum: a modified group judgment method;Perry;Int J Technol Assess Health Care,1992

5. Group techniques for program planning: a guide to nominal group and Delphi processes;Delbecq,1975

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Stem Cell Transplantation for Myelofibrosis;Current Hematologic Malignancy Reports;2024-09-06

2. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

4. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study;Blood Advances;2024-08-14

5. Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review;Expert Review of Hematology;2024-08-13